RECRUITINGOBSERVATIONAL
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Patisiran-LNP Pregnancy Surveillance Program
About This Trial
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Who May Be Eligible (Plain English)
Who May Qualify:
- Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy
Who Should NOT Join This Trial:
- There are no exclusion criteria for participation in this program.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy
Exclusion Criteria:
* There are no exclusion criteria for participation in this program.
Locations (7)
Clinical Trial Site
Iowa City, Iowa, United States
Clinical Trial Site
Nantes, France
Clinical Trial Site
Münster, Germany
Clinical Trial Site
Pavia, Italy
Clinical Trial Site
Groningen, Netherlands
Clinical Trial Site
Lisbon, Portugal
Clinical Trial Site
Madrid, Spain